BTK and B-cell chronic lymphocytic leukemia: In 2019, Jain et al. published the results from a phase II study (NCT02756897) evaluating the combination of venetoclax and the BTK inhibitor ibrutinib in 80 previously untreated, high-risk, older patients with CLL.